Bristol Myers Squibb's Latest Data Could Help the Pharma Leapfrog Rival Merck

In this video from Motley Fool Live, recorded on March 29, Fool.com contributors Brian Orelli and Keith Speights discuss how Bristol Myers Squibb (NYSE: BMY) can maximize the value of its LAG-3 inhibitor, relatlimab, now that the pharmaceutical company has shown it works with its PD-1 drug, Opdivo. On the flip side, the loser here could be Merck (NYSE: MRK), which has a PD-1 drug, Keytruda, but is currently lagging Bristol Myers Squibb in the LAG-3 arena.

Continue reading

Source Fool.com